Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 17Plasma cell 5Gastrointestinal 3Other hematologic neoplasm 2Myeloid 2Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Venous Thromboembolism 1Thrombosis 1Head and Neck Neoplasms 1

Interventions

Cisplatin 416Radiotherapy 240Radiotherapy, Intensity-Modulated 178Cetuximab 177Docetaxel 166pembrolizumab 148Carboplatin 121Fluorouracil 113Paclitaxel 90Nivolumab 82Gemcitabine 82Radiation 72Surveys and Questionnaires 71Drug Therapy 70toripalimab 68Surgical Procedures, Operative 64Magnetic Resonance Spectroscopy 63Capecitabine 50Blood Specimen Collection 50Chemoradiotherapy 46Biopsy 44camrelizumab 41durvalumab 40Radiosurgery 40Standard of Care 38Erlotinib Hydrochloride 34nimotuzumab 32130-nm albumin-bound paclitaxel 32tislelizumab 31apatinib 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × apixaban × Head & Neck × Clear all
NCT07189897 2025-10-08

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

State University of New York - Upstate Medical University

Phase 4 Recruiting
76 enrolled
Classical hematologyHead & Neck

Head and Neck Neoplasms, Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡